Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder

Y. Levkovitz, Jonathan E. Alpert, C. E. Brintz, D. Mischoulon, G. I. Papakostas

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Major depressive disorder (MDD) is often accompanied by significant cognitive impairment, and there are limited interventions specific to this particular symptom. S-adenosylmethionine (SAMe), a naturally occurring molecule which serves as a major methyl-donor in human cellular metabolism, is required for the synthesis and maintenance of several neurotransmitters that have been implicated in the pathophysiology and treatment of cognitive dysfunction in MDD. Objectives: This study is a secondary analysis of a clinical trial involving the use of adjunctive SAMe for MDD. Methods: Forty-six serotonin-reuptake inhibitor (SRI) non-responders with MDD enrolled in a 6-week, double-blind, randomized trial of adjunctive oral SAMe were administered the self-rated cognitive and physical symptoms questionnaire (CPFQ), a validated measure of cognitive as well as physical symptoms of MDD, before and after treatment. Results: There was a greater improvement in the ability to recall information (P=0.04) and a trend towards statistical significance for greater improvement in word-finding (P=0.09) for patients who received adjunctive SAMe than placebo. None of the remaining five items reached statistical significance. Conclusions: These preliminary data suggest that SAMe can improve memory-related cognitive symptoms in depressed patients, and warrant replication.

Original languageEnglish (US)
Pages (from-to)518-521
Number of pages4
JournalEuropean Psychiatry
Volume27
Issue number7
DOIs
StatePublished - Oct 2012
Externally publishedYes

Fingerprint

S-Adenosylmethionine
Neurobehavioral Manifestations
Major Depressive Disorder
Serotonin Uptake Inhibitors
Antidepressive Agents
Aptitude
Neurotransmitter Agents
Placebos
Maintenance
Tissue Donors
Clinical Trials
Therapeutics

Keywords

  • Cognitive function
  • Major depression
  • One-carbon cycle
  • Pharmacotherapy
  • S-adenosylmethionine

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. / Levkovitz, Y.; Alpert, Jonathan E.; Brintz, C. E.; Mischoulon, D.; Papakostas, G. I.

In: European Psychiatry, Vol. 27, No. 7, 10.2012, p. 518-521.

Research output: Contribution to journalArticle

@article{0a5824e02a87429f8e17cc3575b4834b,
title = "Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder",
abstract = "Major depressive disorder (MDD) is often accompanied by significant cognitive impairment, and there are limited interventions specific to this particular symptom. S-adenosylmethionine (SAMe), a naturally occurring molecule which serves as a major methyl-donor in human cellular metabolism, is required for the synthesis and maintenance of several neurotransmitters that have been implicated in the pathophysiology and treatment of cognitive dysfunction in MDD. Objectives: This study is a secondary analysis of a clinical trial involving the use of adjunctive SAMe for MDD. Methods: Forty-six serotonin-reuptake inhibitor (SRI) non-responders with MDD enrolled in a 6-week, double-blind, randomized trial of adjunctive oral SAMe were administered the self-rated cognitive and physical symptoms questionnaire (CPFQ), a validated measure of cognitive as well as physical symptoms of MDD, before and after treatment. Results: There was a greater improvement in the ability to recall information (P=0.04) and a trend towards statistical significance for greater improvement in word-finding (P=0.09) for patients who received adjunctive SAMe than placebo. None of the remaining five items reached statistical significance. Conclusions: These preliminary data suggest that SAMe can improve memory-related cognitive symptoms in depressed patients, and warrant replication.",
keywords = "Cognitive function, Major depression, One-carbon cycle, Pharmacotherapy, S-adenosylmethionine",
author = "Y. Levkovitz and Alpert, {Jonathan E.} and Brintz, {C. E.} and D. Mischoulon and Papakostas, {G. I.}",
year = "2012",
month = "10",
doi = "10.1016/j.eurpsy.2011.03.006",
language = "English (US)",
volume = "27",
pages = "518--521",
journal = "European Psychiatry",
issn = "0924-9338",
publisher = "Elsevier Masson",
number = "7",

}

TY - JOUR

T1 - Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder

AU - Levkovitz, Y.

AU - Alpert, Jonathan E.

AU - Brintz, C. E.

AU - Mischoulon, D.

AU - Papakostas, G. I.

PY - 2012/10

Y1 - 2012/10

N2 - Major depressive disorder (MDD) is often accompanied by significant cognitive impairment, and there are limited interventions specific to this particular symptom. S-adenosylmethionine (SAMe), a naturally occurring molecule which serves as a major methyl-donor in human cellular metabolism, is required for the synthesis and maintenance of several neurotransmitters that have been implicated in the pathophysiology and treatment of cognitive dysfunction in MDD. Objectives: This study is a secondary analysis of a clinical trial involving the use of adjunctive SAMe for MDD. Methods: Forty-six serotonin-reuptake inhibitor (SRI) non-responders with MDD enrolled in a 6-week, double-blind, randomized trial of adjunctive oral SAMe were administered the self-rated cognitive and physical symptoms questionnaire (CPFQ), a validated measure of cognitive as well as physical symptoms of MDD, before and after treatment. Results: There was a greater improvement in the ability to recall information (P=0.04) and a trend towards statistical significance for greater improvement in word-finding (P=0.09) for patients who received adjunctive SAMe than placebo. None of the remaining five items reached statistical significance. Conclusions: These preliminary data suggest that SAMe can improve memory-related cognitive symptoms in depressed patients, and warrant replication.

AB - Major depressive disorder (MDD) is often accompanied by significant cognitive impairment, and there are limited interventions specific to this particular symptom. S-adenosylmethionine (SAMe), a naturally occurring molecule which serves as a major methyl-donor in human cellular metabolism, is required for the synthesis and maintenance of several neurotransmitters that have been implicated in the pathophysiology and treatment of cognitive dysfunction in MDD. Objectives: This study is a secondary analysis of a clinical trial involving the use of adjunctive SAMe for MDD. Methods: Forty-six serotonin-reuptake inhibitor (SRI) non-responders with MDD enrolled in a 6-week, double-blind, randomized trial of adjunctive oral SAMe were administered the self-rated cognitive and physical symptoms questionnaire (CPFQ), a validated measure of cognitive as well as physical symptoms of MDD, before and after treatment. Results: There was a greater improvement in the ability to recall information (P=0.04) and a trend towards statistical significance for greater improvement in word-finding (P=0.09) for patients who received adjunctive SAMe than placebo. None of the remaining five items reached statistical significance. Conclusions: These preliminary data suggest that SAMe can improve memory-related cognitive symptoms in depressed patients, and warrant replication.

KW - Cognitive function

KW - Major depression

KW - One-carbon cycle

KW - Pharmacotherapy

KW - S-adenosylmethionine

UR - http://www.scopus.com/inward/record.url?scp=84866465151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866465151&partnerID=8YFLogxK

U2 - 10.1016/j.eurpsy.2011.03.006

DO - 10.1016/j.eurpsy.2011.03.006

M3 - Article

VL - 27

SP - 518

EP - 521

JO - European Psychiatry

JF - European Psychiatry

SN - 0924-9338

IS - 7

ER -